Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.88 +0.23 (+0.90%)
Official Closing Price Updated: 7:00 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
Via Stocktwits
News headline image
Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock ↗
 
Via Benzinga
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
The Best Stocks to Invest $40 in to Start the New Year Off Right ↗
Both could reward patient investors down the line. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
AGG vs. VCIT: The Same Tiny Fee, Completely Different Holdings ↗
Explore how portfolio breadth and risk profiles set these two leading bond ETFs apart for income-focused investors. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
Pfizer CEO Calls RFK&#39;s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research ↗
Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness. 
Via Benzinga
News headline image
The HSR Paradox: How 'Early Termination' is Reshaping the 2026 M&A Landscape
A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Top Stock to Buy With $30 for 2026 ↗
It's a great opportunity to "buy low." 
Via The Motley Fool
Topics Intellectual Property
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
Via Finterra
Topics Intellectual Property
News headline image
The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally... 
Via MarketMinute
Topics Economy
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗
Via Chartmill
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
How Is The Market Feeling About Pfizer Inc? ↗
 
Via Benzinga
News headline image
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? ↗
The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is This Dividend King Stock a Buy After a Major Development? ↗
After a strong performance in 2025, Johnson & Johnson is starting the new year right. 
Via The Motley Fool
Topics Government World Trade
News headline image
Why Are Novavax (NVAX) Shares Soaring Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the... 
Via TokenRing AI
Topics Artificial Intelligence Economy Intellectual Property
News headline image
J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,... 
Via MarketMinute
Topics Earnings Economy Government
News headline image
3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer ↗
One of these suggested stocks features a dividend yield topping 10%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?
The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark... 
Via MarketMinute
Topics Economy Supply Chain World Trade
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Novavax Shares Rise After Licensing Deal With Pfizer ↗
Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant. 
Via Benzinga
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.